You are here
Articles on Chemotherapy & Chemoradiotherapy in Gastric Cancer
This section of the Advances in Gastrointestinal Cancer Resource Centre focuses on the latest clinically relevant findings in chemotherapy and chemoradiotherapy for gastrointestinal cancers. The peer-reviewed articles available here have been independently selected, and several commented upon, by members of the Editorial Board. Many of the articles are freely available for downloading.
Focusing initially on gastric cancer, these pages will provide new content each month to help you stay abreast of recent scientific developments in this area.
The use of chemotherapy or chemoradiotherapy (or both) is currently recommended for the treatment of gastric cancer in guidelines from both the USA (NCCN) and Europe (ESMO-ESSO-ESTRO).1 Depending on tumour stage and resectability, patients may be given chemotherapy or chemoradiotherapy preoperatively, postoperatively, or as an adjuvant therapy. Recommended second-line chemotherapy options include irinotecan and docetaxel or paclitaxel. Palliative therapy for inoperable or metastatic gastric cancer may include fluoropyrimidine- or taxane-based chemoradiotherapy or chemotherapy.
Other chemotherapeutic options depend on the patient's HER-2 status. Combination regimens based on a platinum–fluoropyrimidine doublet are generally used for HER-2 negative disease, possibly also with an anthracycline (e.g. epirubicin). Trastuzumab plus cisplatin and either 5-fluorouracil or capecitabine are recommended for HER-2 positive disease.
Treatment options are continually expanding, through use of new combinations of existing or novel therapies, new drugs or treatment approaches, and different ways of administering therapy.
To stay abreast of the most recent developments and clinical trial findings in the use of chemotherapy and chemoradiotherapy for the treatment of gastrointestinal cancers, please subscribe to our eAlert to ensure you are informed of all new content as it is published on this platform.
ESMO-ESSO-ESTRO: European Society for Medical Oncology, European Society of Surgical Oncology, and European Society for Therapeutic Radiology and Oncology; HER-2, human epidermal growth factor receptor 2; NCCN: (US) National Comprehensive Cancer Network.
1. Cabebe EC. Gastric cancer treatment & management. Approach considerations. In Medscape: Drugs & Diseases. Available from: http://emedicine.medscape.com/article/278744-treatment. Last updated 11 Nov 2015; accessed 7 Apr 2016.
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al.Lancet Oncol. 2016 Mar;17(3):309-18
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al.J Clin Oncol. 2016 Feb 16. [Epub ahead of print]
Impact of number of [(18) F]fluorodeoxyglucose-PET-positive lymph nodes on survival of patients receiving neoadjuvant chemotherapy and surgery for oesophageal cancer
Miyata H, Yamasaki M, Makino T, Tatsumi M, Miyazaki Y, Takahashi T, et al.Br J Surg. 2016 Jan;103(1):97-104.
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial
Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al.BMC Cancer. 2016 Feb 8;16(1):68.
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level data
Janowitz T, Thuss-Patience P, Marshall A, Kang JH, Connell C, Cook N, et al.Br J Cancer. 2016 Feb 16;114(4):381-7.
Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials
Salvatore Galdy, Chiara Alessandra Cella, Francesca Spada, Sabina Murgioni, Anna Maria Frezza, Simona Paola Ravenda, Maria Giulia Zampino, Nicola Fazio
Critical Reviews in Oncology/Hematology, In Press, Corrected Proof, Available online 30 November 2015, Available online 30 November 2015
Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?
Elizabeth C. Smyth, Noelia Tarazona, Clare Peckitt, Edward Armstrong, Sonia Mansukhani, David Cunningham, Ian Chau
Clinical Colorectal Cancer, In Press, Corrected Proof, Available online 27 November 2015, Available online 27 November 2015
Prognostic value of neutrophil to lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial
Grenader T, Waddell T, Peckitt C, Oates J, Starling N, Cunningham D, Bridgewater J.Ann Oncol. 2016 Jan 19 [Epub ahead of print]
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy
Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, et al.Gastric Cancer. 2016 Jan 21. [Epub ahead of print]
The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
Ter Veer E, Mohammad NH, Lodder P, Ngai LL, Samaan M, van Oijen MG, van Laarhoven HW.Gastric Cancer 2016 Jan 11. [Epub ahead of print]